The Global Immunology Partnering 2010-2016: Deal trends,
players and financials report provides comprehensive understanding and
unprecedented access to the immunology/autoimmune partnering deals and
agreements entered into by the worlds leading healthcare companies
Description
Global Immunology Partnering 2010 to 2016 provides the full
collection of Immunology disease deals signed between the world’s
pharmaceutical and biotechnology companies since 2010.
- Trends in Immunology partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Immunology partnering agreement structure
- Immunology partnering contract documents
- Top Immunology deals by value
- Most active Immunology dealmakers
Most of the deals included within the report occur when a
licensee obtains a right or an option right to license a licensor’s product or
technology. More often these days these deals tend to be multi-component
including both a collaborative R&D and a commercialization of outcomes
element.
The report takes readers through the comprehensive
Immunology disease deal trends, key players and top deal values allowing the
understanding of how, why and under what terms companies are currently entering
Immunology deals.
The report presents financial deal terms values for
Immunology deals, where available listing by overall headline values, upfront
payments, milestones and royalties enabling readers to analyse and benchmark
the value of current deals.
The initial chapters of this report provide an orientation
of Immunology dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Immunology
dealmaking since 2010 covering trends by year, deal type, stage of development,
technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms
covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Immunology deals
since 2010. Deals are listed by headline value. The chapter includes the top 25
most active Immunology dealmakers, together with a full listing of deals to
which they are a party. Where the deal has an agreement contract published at
the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Immunology deals
since 2010 where a deal contract is available, providing the user with direct
access to contracts as filed with the SEC regulatory authorities. Each deal
title links via Weblink to an online version of the deal record contract
document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all
Immunology partnering deals by specific Immunology target announced since 2010.
The chapter is organized by specific Immunology therapeutic target. Each deal
title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each contract
document on demand.
In addition, a comprehensive appendix is provided with each
report of all Immunology partnering deals signed and announced since 2010. The
appendices are organized by company A-Z, stage of development at signing, deal
type (collaborative R&D, co-promotion, licensing etc) and technology type.
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
The report also includes numerous tables and figures that
illustrate the trends and activities in Immunology partnering and dealmaking
since 2010.
In conclusion, this report provides everything a prospective
dealmaker needs to know about partnering in the research, development and
commercialization of Immunology technologies and products.
Report scope
Global Immunology Partnering 2010 to 2016 is intended to
provide the reader with an in-depth understanding and access to Immunology
trends and structure of deals entered into by leading companies worldwide.
Global Immunology Partnering 2010 to 2016 includes:
- Trends in Immunology dealmaking in the biopharma industry since 2010
- Analysis of Immunology deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Immunology deal contract documents
- Comprehensive access to over 3500 Immunology deal records
- The leading Immunology deals by value since 2010
- Most active Immunology dealmakers since 2010
The report includes deals for the following indications:
AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation,
Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other
immunology indications.
In Global Immunology Partnering 2010 to 2016, available
deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
The Global Immunology Partnering 2010-2016 report provides
comprehensive access to available deals and contract documents for over 700
immunology deals. Analyzing actual contract agreements allows assessment of the
following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Global Immunology Partnering 2010 to 2016 provides the
reader with the following key benefits:
- In-depth understanding of Immunology deal trends since 2010
- Access Immunology deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between Immunology partner companies
- Comprehensive access to over 750 links to actual Immunology deals entered into by the world’s biopharma companies
- Indepth review of Immunology deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner Immunology opportunities
- Uncover companies actively partnering Immunology opportunities
Spanning over 1000 pages “Global Immunology
Partnering 2010-2016: Deal trends, players and financials” report covers Executive
Summary, Introduction, Trends in Immunology dealmaking, Financial deal terms
for Immunology partnering, Leading Immunology deals and dealmakers, Immunology
contract document directory, Immunology dealmaking by therapeutic target,
Appendices.
For
more information Visit at: http://mrr.cm/3JC
Related Reports;
Global Hospital Care Partnering 2010-2016: Deal trends,
players and financials - Visit at - http://mrr.cm/3Jy
Global Bacterial Partnering
2010-2016: Deal trends, players and financials - Visit at - http://mrr.cm/3JF
Global Viral Partnering 2010-2016: Deal trends, players and
financials - Visit at - http://mrr.cm/3Jt
Global Obstetrics Partnering 2010-2016: Deal trends, players
and financials - Visit at - http://mrr.cm/3Jv
No comments:
Post a Comment
Note: only a member of this blog may post a comment.